Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy.

[1]  A. López-Guillermo,et al.  Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment , 2018, Hematological oncology.

[2]  N. Schmitz,et al.  Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  Sonali M. Smith,et al.  Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  E. González-Barca,et al.  Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome , 2017, Hematological oncology.

[5]  A. López-Guillermo,et al.  Progression‐free survival at 2 years post‐autologous transplant: a surrogate end point for overall survival in follicular lymphoma , 2017, Cancer medicine.

[6]  A. López-Guillermo,et al.  Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  Julio Delgado,et al.  Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group , 2017, British journal of haematology.

[8]  G. Salles,et al.  Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. , 2017, Blood.

[9]  J. Cerhan,et al.  Early event status informs subsequent outcome in newly diagnosed follicular lymphoma , 2016, American journal of hematology.

[10]  H. Einsele,et al.  Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Rosenwald,et al.  Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. , 2016, Blood.

[12]  J. Gribben,et al.  Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. , 2016, The Lancet. Oncology.

[13]  Y. Yatabe,et al.  Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy , 2016, Annals of Hematology.

[14]  J. Cerhan,et al.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Michael L. Wang,et al.  Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. , 2014, The Lancet. Oncology.

[17]  V. Kukreti,et al.  Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis , 2014, Leukemia & lymphoma.

[18]  L. Gordon,et al.  Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab , 2013, Cancer.

[19]  Summer S. Han,et al.  Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. , 2013, Blood.

[20]  G. Salles,et al.  Impact of the use of autologous stem cell transplantation at first relapse both in naïve and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study , 2011, Haematologica.

[21]  S. Montoto,et al.  Transformation of indolent B-cell lymphomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Andrew Lister,et al.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.

[23]  R. Marcus,et al.  Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. Coiffier,et al.  Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Ittel,et al.  Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Salles,et al.  Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 2006, Blood.

[27]  G. Ayers,et al.  Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Lynch,et al.  Improved survival of follicular lymphoma patients in the United States. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Sydes,et al.  High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Lister.  High-dose therapy for follicular lymphoma revisited: not if, but when? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  N. Schmitz,et al.  Survival and Freedom from Progression in Autotransplant Lymphoma Patients is Independent of Stem Cell Source: Further Follow-up from the Original Randomised Study to Assess Engraftment , 2002, Leukemia & lymphoma.

[32]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  N. Schmitz,et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.

[34]  N. Harris,et al.  Lymphoma classification proposal: clarification. , 1995, Blood.

[35]  Mark Stevenson,et al.  Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. , 2012, Health technology assessment.

[36]  D. Weisenburger,et al.  Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  T. Lister,et al.  Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.